Divided 8th Circuit Panel Partially Reverses Dismissal Of Baycol Qui Tam Case

Divided 8th Circuit Panel Partially Reverses Dismissal Of Baycol Qui Tam Case

ST. LOUIS - A divided federal appeals panel on Oct. 15 reversed dismissal of a whistle-blower's claims that Bayer Healthcare defrauded the U.S. Department of Defense (DoD) by misrepresenting that its former cholesterol-lowering drug Baycol was as effective as competing drugs and that it did not cause muscle damage (In Re: Baycol Litigation, United States of America, ex rel. Laurie Simpson v. Bayer Healthcare, et al., No. 12-2979, 8th Cir.).

Find full version on lexis Advance®
Access this news story on lexis.com®